Financhill
Sell
45

BIB Quote, Financials, Valuation and Earnings

Last price:
$46.50
Seasonality move :
11.71%
Day range:
$46.22 - $47.14
52-week range:
$33.78 - $69.56
Dividend yield:
2.04%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
3.9K
Avg. volume:
11K
1-year change:
-11.92%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIB
ProShares Ultra Nasdaq Biotechnology
-- -- -- -- --
QLD
ProShares Ultra QQQ
-- -- -- -- --
SKYU
ProShares Ultra Nasdaq Cloud Computing
-- -- -- -- --
TQQQ
ProShares UltraPro QQQ
-- -- -- -- --
UCYB
ProShares Ultra Nasdaq Cybersecurity
-- -- -- -- --
URE
ProShares Ultra Real Estate
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIB
ProShares Ultra Nasdaq Biotechnology
$46.31 -- -- -- $0.13 2.04% --
QLD
ProShares Ultra QQQ
$90.75 -- -- -- $0.03 0.27% --
SKYU
ProShares Ultra Nasdaq Cloud Computing
$25.84 -- -- -- $0.01 0.31% --
TQQQ
ProShares UltraPro QQQ
$56.77 -- -- -- $0.20 1.74% --
UCYB
ProShares Ultra Nasdaq Cybersecurity
$49.28 -- -- -- $0.14 2.15% --
URE
ProShares Ultra Real Estate
$63.27 -- -- -- $0.26 2.4% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIB
ProShares Ultra Nasdaq Biotechnology
-- 1.798 -- --
QLD
ProShares Ultra QQQ
-- 2.195 -- --
SKYU
ProShares Ultra Nasdaq Cloud Computing
-- 3.730 -- --
TQQQ
ProShares UltraPro QQQ
-- 3.353 -- --
UCYB
ProShares Ultra Nasdaq Cybersecurity
-- 1.285 -- --
URE
ProShares Ultra Real Estate
-- 1.751 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIB
ProShares Ultra Nasdaq Biotechnology
-- -- -- -- -- --
QLD
ProShares Ultra QQQ
-- -- -- -- -- --
SKYU
ProShares Ultra Nasdaq Cloud Computing
-- -- -- -- -- --
TQQQ
ProShares UltraPro QQQ
-- -- -- -- -- --
UCYB
ProShares Ultra Nasdaq Cybersecurity
-- -- -- -- -- --
URE
ProShares Ultra Real Estate
-- -- -- -- -- --

ProShares Ultra Nasdaq Biotechnology vs. Competitors

  • Which has Higher Returns BIB or QLD?

    ProShares Ultra QQQ has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra QQQ's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- --
    QLD
    ProShares Ultra QQQ
    -- -- --
  • What do Analysts Say About BIB or QLD?

    ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra QQQ, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra QQQ.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIB
    ProShares Ultra Nasdaq Biotechnology
    0 0 0
    QLD
    ProShares Ultra QQQ
    0 0 0
  • Is BIB or QLD More Risky?

    ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra QQQ has a beta of 2.349, suggesting its more volatile than the S&P 500 by 134.941%.

  • Which is a Better Dividend Stock BIB or QLD?

    ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.04%. ProShares Ultra QQQ offers a yield of 0.27% to investors and pays a quarterly dividend of $0.03 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra QQQ pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIB or QLD?

    ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra QQQ quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra QQQ's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra QQQ. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- -- --
    QLD
    ProShares Ultra QQQ
    -- -- -- --
  • Which has Higher Returns BIB or SKYU?

    ProShares Ultra Nasdaq Cloud Computing has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Nasdaq Cloud Computing's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- --
    SKYU
    ProShares Ultra Nasdaq Cloud Computing
    -- -- --
  • What do Analysts Say About BIB or SKYU?

    ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Nasdaq Cloud Computing has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Nasdaq Cloud Computing, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Nasdaq Cloud Computing.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIB
    ProShares Ultra Nasdaq Biotechnology
    0 0 0
    SKYU
    ProShares Ultra Nasdaq Cloud Computing
    0 0 0
  • Is BIB or SKYU More Risky?

    ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Nasdaq Cloud Computing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIB or SKYU?

    ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.04%. ProShares Ultra Nasdaq Cloud Computing offers a yield of 0.31% to investors and pays a quarterly dividend of $0.01 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Nasdaq Cloud Computing pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIB or SKYU?

    ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Nasdaq Cloud Computing quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Nasdaq Cloud Computing's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Nasdaq Cloud Computing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Nasdaq Cloud Computing. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- -- --
    SKYU
    ProShares Ultra Nasdaq Cloud Computing
    -- -- -- --
  • Which has Higher Returns BIB or TQQQ?

    ProShares UltraPro QQQ has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares UltraPro QQQ's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- --
    TQQQ
    ProShares UltraPro QQQ
    -- -- --
  • What do Analysts Say About BIB or TQQQ?

    ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares UltraPro QQQ has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares UltraPro QQQ, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares UltraPro QQQ.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIB
    ProShares Ultra Nasdaq Biotechnology
    0 0 0
    TQQQ
    ProShares UltraPro QQQ
    0 0 0
  • Is BIB or TQQQ More Risky?

    ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares UltraPro QQQ has a beta of 3.522, suggesting its more volatile than the S&P 500 by 252.185%.

  • Which is a Better Dividend Stock BIB or TQQQ?

    ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.04%. ProShares UltraPro QQQ offers a yield of 1.74% to investors and pays a quarterly dividend of $0.20 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares UltraPro QQQ pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIB or TQQQ?

    ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares UltraPro QQQ quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares UltraPro QQQ's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares UltraPro QQQ's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares UltraPro QQQ. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- -- --
    TQQQ
    ProShares UltraPro QQQ
    -- -- -- --
  • Which has Higher Returns BIB or UCYB?

    ProShares Ultra Nasdaq Cybersecurity has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Nasdaq Cybersecurity's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- --
    UCYB
    ProShares Ultra Nasdaq Cybersecurity
    -- -- --
  • What do Analysts Say About BIB or UCYB?

    ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Nasdaq Cybersecurity has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Nasdaq Cybersecurity, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Nasdaq Cybersecurity.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIB
    ProShares Ultra Nasdaq Biotechnology
    0 0 0
    UCYB
    ProShares Ultra Nasdaq Cybersecurity
    0 0 0
  • Is BIB or UCYB More Risky?

    ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Nasdaq Cybersecurity has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIB or UCYB?

    ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.04%. ProShares Ultra Nasdaq Cybersecurity offers a yield of 2.15% to investors and pays a quarterly dividend of $0.14 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Nasdaq Cybersecurity pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIB or UCYB?

    ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Nasdaq Cybersecurity quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Nasdaq Cybersecurity's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Nasdaq Cybersecurity's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Nasdaq Cybersecurity. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- -- --
    UCYB
    ProShares Ultra Nasdaq Cybersecurity
    -- -- -- --
  • Which has Higher Returns BIB or URE?

    ProShares Ultra Real Estate has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Real Estate's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- --
    URE
    ProShares Ultra Real Estate
    -- -- --
  • What do Analysts Say About BIB or URE?

    ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Real Estate has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Real Estate, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Real Estate.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIB
    ProShares Ultra Nasdaq Biotechnology
    0 0 0
    URE
    ProShares Ultra Real Estate
    0 0 0
  • Is BIB or URE More Risky?

    ProShares Ultra Nasdaq Biotechnology has a beta of 1.365, which suggesting that the stock is 36.499% more volatile than S&P 500. In comparison ProShares Ultra Real Estate has a beta of 1.986, suggesting its more volatile than the S&P 500 by 98.588%.

  • Which is a Better Dividend Stock BIB or URE?

    ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.13 per share corresponding to a yield of 2.04%. ProShares Ultra Real Estate offers a yield of 2.4% to investors and pays a quarterly dividend of $0.26 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Real Estate pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIB or URE?

    ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Real Estate quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Real Estate's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Real Estate's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Real Estate. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIB
    ProShares Ultra Nasdaq Biotechnology
    -- -- -- --
    URE
    ProShares Ultra Real Estate
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is down 14.73% over the past day.

Buy
65
MYRG alert for May 2

MYR Group [MYRG] is up 1.7% over the past day.

Sell
35
FTAI alert for May 2

FTAI Aviation [FTAI] is up 8.67% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock